Immune cell therapy takes on kidney disease

This early-phase trial tests a new treatment called KN5501, which uses specially engineered immune cells (CAR NK cells) to target and destroy harmful B cells in people with relapsed or refractory immune nephropathy, a kidney disease caused by the immune system attacking the kidneys. The study will enroll 36 adults and primarily check for safety and side effects, while also looking at whether the treatment can control the disease. Participants will receive chemotherapy before the cell infusion to help the cells work.